Effect of tacrolimus in a patient with pure red-cell aplasia

Clinical and Laboratory Haematology

Volumn 27, Issue 1, 2005, Pages 67-69

  Yoshida, S ^a   Konishi, Tetsuro ^a   Nishizawa, T ^b   Yoshida, Y ^b  

^a UTANO NATIONAL HOSPITAL   (Japan)

^b TAKEDA GENERAL HOSPITAL   (Japan)

Author keywords

Corticosteroids; Myasthenia gravis; Pure red cell aplasia; Tacrolimus; Thymoma

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; TACROLIMUS;

AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW CELL; CASE REPORT; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; ERYTHROID CELL; FEMALE; HUMAN; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SIDE EFFECT; THYMOMA; TREATMENT INDICATION;

AGED; ANEMIA; CYCLOSPORINE; DISEASE PROGRESSION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; KIDNEY; MYASTHENIA GRAVIS; RED-CELL APLASIA, PURE; REMISSION INDUCTION; TACROLIMUS; THYMOMA;

EID: 14344259512     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2004.00654.x     Document Type: Article

References (13)

1. Bailey R.O., Dunn H.G., Rubin A.M. & Ritaccio A.L. (1988) Myasthenia gravis with thymoma and pure red blood cell aplasia. American Journal of Clinical Pathology 89, 687-693.
2. Drachman D.B. (1994) Myasthenia gravis. New England Journal of Medicine 330, 1797-1810.
3. Erslev A.J. & Soltan A. (1996) Pure red-cell aplasia: a review. Blood Reviews 10, 20-28.
4. Evoli A., Schino C.D., Marsili F. & Punzi C. (2002) Successful treatment of myasthenia gravis with tacrolimus. Muscle & Nerve 25, 111-114.
5. Jaretzki A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S. & Sanders D.B. (2000) Myasthenia gravis. Recommendation for clinical research standards. Neurology 55, 16-23.
6. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H. & Imanaka H. (1987) FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. Journal of Antibiotics (Tokyo) 40, 1249-1255.
7. Konishi T., Yoshiyama Y., Takamori M., Yagi K., Mukai E. & Saida T. (2003) A clinical study of FK506 in patients with myasthenia gravis. Muscle & Nerve 28, 570-574.
8. Migita K., Eguchi K., Kawabe Y., Origuchi T., Tominaga M. & Nagataki S. (1997) FK506 potentiates steroid-induced T-cell apoptosis. Transplantation 64, 1365-1369.
9. Misra S., Moore T.B., Ament M.E., Busuttil R.W. & McDiarmid S.V. (1998) Red cell aplasia in children on tacrolimus after liver transplantation. Transplantation 65, 575-577.
10. Ning Y.-M. & Sánchez E.R. (1993) Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. Journal of Biological Chemistry 268, 6073-6077.
11. Schreiber S.L. & Crabtree G.R. (1992) The mechanism of action of cyclosporin A and FK506. Immunology Today 13, 136-142.
12. Suzuki S., Osaka Y., Nakai I., Yasumura T., Omori Y., Yamagata N., Shimazaki C. & Oka T. (1996) Pure red cell aplasia induced by FK506. Transplantation 61, 831-844.
13. Thomson A.W., Bonham C.A. & Zeevi A. (1995) Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Therapeutic Drug Monitoring 17, 584-591.